HC Wainwright Issues Negative Estimate for FibroGen Earnings

FibroGen, Inc (NASDAQ:FGEN) – HC Wainwright reduced their Q3 2025 earnings estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst M. Keller now expects that the biopharmaceutical company will post earnings of ($2.21) per share for the quarter, down from their previous forecast of $0.62. HC Wainwright has a “Buy” rating and a $43.00 price objective on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q4 2025 earnings at ($2.59) EPS, FY2025 earnings at ($10.84) EPS, FY2026 earnings at ($8.27) EPS, FY2027 earnings at ($8.37) EPS and FY2028 earnings at ($8.41) EPS.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Monday, August 11th. The biopharmaceutical company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.25) by ($1.13). The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.88 million.

Separately, Wall Street Zen lowered shares of FibroGen from a “hold” rating to a “sell” rating in a report on Saturday.

FibroGen Stock Performance

Shares of FGEN stock opened at $9.49 on Friday. The firm’s 50 day moving average price is $6.95 and its 200-day moving average price is $8.48. FibroGen has a one year low of $4.50 and a one year high of $21.94. The firm has a market cap of $38.38 million, a P/E ratio of -24.97 and a beta of 0.76.

Hedge Funds Weigh In On FibroGen

Several large investors have recently made changes to their positions in the stock. Armistice Capital LLC increased its stake in FibroGen by 25.0% during the 1st quarter. Armistice Capital LLC now owns 8,500,000 shares of the biopharmaceutical company’s stock worth $2,634,000 after buying an additional 1,700,000 shares during the period. Renaissance Technologies LLC increased its stake in FibroGen by 80.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 605,572 shares during the period. Mackenzie Financial Corp increased its stake in FibroGen by 416.6% during the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock worth $290,000 after buying an additional 441,083 shares during the period. Squarepoint Ops LLC purchased a new stake in FibroGen during the 4th quarter worth approximately $205,000. Finally, HighTower Advisors LLC increased its stake in FibroGen by 292.8% during the 1st quarter. HighTower Advisors LLC now owns 404,488 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 301,500 shares during the period. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at FibroGen

In related news, Director James A. Schoeneck acquired 23,567 shares of the firm’s stock in a transaction dated Monday, June 30th. The shares were purchased at an average cost of $5.07 per share, for a total transaction of $119,484.69. Following the acquisition, the director owned 39,666 shares in the company, valued at $201,106.62. The trade was a 146.39% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 3.07% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.